Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharideviainactivation of nuclear factor-κB
- 23 April 2014
- journal article
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 36 (3) , 237-241
Abstract
The effect of spironolactone (SPIR) on lipopolysaccharide (LPS)-induced production of proinflammatory mediators was examined using RAW 264.7 macrophage-like cells and mouse peritoneal macrophages. SPIR significantly inhibited LPS-induced production of nitric oxide (NO), tumor necrosis factor-α and prostaglandin E2. The inhibition was not mediated by cell death. SPIR reduced the expression of an inducible NO synthase mRNA in response to LPS. SPIR significantly inhibited phosphorylation of p65 nuclear factor (NF)-κB in response to LPS. Furthermore, SPIR inhibited phosphorylation of IκB kinase (IKK) as an upstream molecule of NF-κB in response to LPS. LPS did not induce the production of aldosterone in RAW 264.7 cells. Taken together, SPIR is suggested to inhibit LPS-induced proinflammatory mediators via inactivation of IKK/NF-κB in LPS signaling.Keywords
This publication has 25 references indexed in Scilit:
- Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failureInternational Journal of Cardiology, 2014
- Targeting Toll-Like Receptors: Promising Therapeutic Strategies for the Management of Sepsis-Associated Pathology and Infectious DiseasesFrontiers in Immunology, 2013
- Effect of Spironolactone on Patients With Atrial Fibrillation and Structural Heart DiseaseClinical Cardiology, 2011
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose DietEndocrinology, 2010
- Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic RatsJournal of the American Society of Nephrology, 2006
- Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cellsImmunology Letters, 2004
- Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-α and interferon-γ, and has potential in the treatment of arthritisClinical and Experimental Immunology, 2003
- The spironolactone renaissanceExpert Opinion on Investigational Drugs, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999